On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Recursion Pharmaceuticals had a busy start to the week, scrapping a rare disease asset from its pipeline as part of a strategic rethink while pulling in a $150 million private placement. The ...
Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. RXRX stock looks like a deep-value growth bet at just $5 ...
This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback